BCL-2 PROTEIN EXPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

Thesis

submitted for the partial fulfillment of

Master Degree in Clinical and Chemical Pathology

By

Salwa Mohamed Ibrahiem

Supervisors

Prof. Dr. MONA MOHAMED RAFIK

Professor of Clinical Pathology

Prof. Dr. MOHAMED FATHY TAMARA

Professor of Internal Medicine & Rheumatology

Dr. SHAHIRA FATHY EL-FEDAWI

Lecturer of Clinical Pathology

Faculty of Medicine

Ain Shams University

1997





سورة البقرة .. آيه ٣٢

ACKNOWLEDGEMENT

I wish to express my deep appreciation and gratitude to **Prof. Dr. Mona Mohamed Rafik,** Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her gracious supervision, valuable suggestions and continuous encouragement.

I would like to express special thanks and gratitude to **Prof. Dr. Mohamed Fathy Tamara,** Professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, for his supervision, kind help, valuable observation and generous support.

I would like to express my deep thanks and sincere appreciation to **Dr. Shahira Fathy El-Fedawi,** Lecturer of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her meticulous supervision, sincere effort and outstanding assistance through every step of this study.

I wish to express my deep thanks to **Dr. Nermin Tayseer and Dr. Hanan Owes**, for their great and sincere help and effort during this work.

Last, but not least, I would like to send my best regards and thanks to My Family for their help and continuous encouragement.

ABSTRACT

In the present study, a trial to assess the role of proto-oncogene Bcl-2 in autoimmune diseases was carried out.

This study was done on eighty individuals: seventy patients (40 SLE, 20 collagen diseases and 10 RA patients) and ten controls. The patients were chosen from the Rheumatology and Internal Medicine Outpatient Clinics of Ain Shams University Hospitals.

All patients under study were subjected to clinical and laboratory examination including CBC, ESR, ANA and anti-dsDNA, RF, CRP and Bcl-2 using an ELISA.

The present study demonstrated a significant difference between the control group and each studied group of patients. A significant difference was found between active and inactive and between treated and untreated SLE group of patients.

From this study, we could conclude Bcl-2 can be used as a diagnostic marker in autoimmune diseases. Furthermore, studies in genetic engineering for the production of monoclonal antibody against this protein by homologous recombination and gene construction will be of future benefit in treatment of many pathologic conditions through which Bcl-2 play a major role in its pathogenesis.

LIST OF FIGURES

Fig. (1): .....(7)
Stages of apoptosis in a lymphocyte.

Fig. (2): .....(11)
Three mechanisms by which phagocytes may recognize cells undergoing apoptosis.

Fig. (3): .....(16)
Pathways to apoptosis.

Fig. (4): .....(25)
Structure of the t(14;18) translocation.

Fig. (5): .....(36)
Spectrum of autoimmune diseases.

Fig. (6): .....(59)
Mean values of Bcl-2 in different studied groups.

Fig. (7): .....(62)
Mean values of Bcl-2 in active and inactive SLE group of patients.

Fig. (8): .....(63)
Mean values of Bcl-2 in treated and untreated SLE group of patients.

Fig. (9): .....(66)
Correlation study between Bcl-2 and ESR in SLE group of patients.

Fig. (10): .....(67)
Correlation study between Bcl-2 and ESR in active SLE group of patients.

Fig. (11): .....(68)
Correlation study between Bcl-2 and disease duration in SLE group of patients.

Fig. (12): .....(69)
Correlation study between Bcl-2 and ESR in RA group of patients.

Fig. (13): .....(70)
Correlation study between Bcl-2 and ESR in collagen disease group of patients.

LIST OF TABLES

Table (1): .....(22)
Genes whose expression has been shown to coincide with cell death in at least one tissue.

Table (2): .....(24)
Genes whose expression is directly involved in regulating cell death in at least one cell type.

Table (3): .....(32)
Bcl-2 family.

Table (4): .....(40)
Some autoantigens involved in cellular biosynthetic functions.

Table (5): .....(58)
Comparison between the mean values of Bcl-2 in different groups versus control.

Table (6a): .....(60)
Descriptive statistics for inactive SLE patients (n=21).

Table (6b): .....(60)
Descriptive statistics for active SLE patients (n=19).

Table (7a): .....(61)
Comparison between active and inactive SLE patients regarding Bcl-2.

Table (7b): .....(61)
Comparison between untreated and treated SLE patients regarding Bcl-2.

Table (8): .....(64)
Comparison between SLE patients with positive CRP and those with negative results as regards Bcl-2 level.

Table (9): .....(64)
Comparison between RA and SLE patients.

Table (10): .....(65)
Comparison between SLE and collagen disease patients.

Table (11): .....(65)
Comparison between collagen disease and RA patients.

CONTENTS

* INTRODUCTION .....(1)

* AIM OF THE WORK .....(2)

* REVIEW OF LITERATURE

  Overview on Apoptosis .....(3)

  Molecular Regulation of Apoptosis .....(16)

  Apoptosis in Autoimmune Diseases .....(35)

* SUBJECTS AND METHODS .....(47)

* RESULTS .....(55)

* DISCUSSION .....(71)

* SUMMARY AND CONCLUSION .....(76)

* RECOMMEDATIONS .....(79)

* REFERENCES .....(80)

* ARABIC SUMMARY.